<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Fed Pract</journal-id><journal-id journal-id-type="iso-abbrev">Fed Pract</journal-id><journal-id journal-id-type="pmc-domain-id">3463</journal-id><journal-id journal-id-type="pmc-domain">fedprac</journal-id><journal-title-group><journal-title>Federal Practitioner</journal-title></journal-title-group><issn pub-type="ppub">1078-4497</issn><issn pub-type="epub">1945-337X</issn><publisher><publisher-name>Frontline Medical Communications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10506496</article-id><article-id pub-id-type="pmcid-ver">PMC10506496.1</article-id><article-id pub-id-type="pmcaid">10506496</article-id><article-id pub-id-type="pmcaiid">10506496</article-id><article-id pub-id-type="pmid">37727827</article-id><article-id pub-id-type="doi">10.12788/fp.0375</article-id><article-id pub-id-type="publisher-id">fp-40-05s-064</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Oropharyngeal Squamous Cell Carcinoma Outcomes by p16<sup>INK4a</sup> Antigen Status in a Veteran Population</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Shires</surname><given-names initials="CB">Courtney B.</given-names></name><degrees>MD</degrees><xref rid="af1-fp-40-05s-064" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tomeh</surname><given-names initials="C">Chafeek</given-names></name><degrees>MD</degrees><xref rid="af2-fp-40-05s-064" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zafar</surname><given-names initials="N">Nadeem</given-names></name><degrees>MD</degrees><xref rid="af3-fp-40-05s-064" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sebelik</surname><given-names initials="ME">Merry E.</given-names></name><degrees>MD</degrees><xref rid="af4-fp-40-05s-064" ref-type="aff">d</xref></contrib></contrib-group><aff id="af1-fp-40-05s-064">
<label>a</label>West Cancer Center, Germantown, Tennessee</aff><aff id="af2-fp-40-05s-064">
<label>b</label>Banner MD Anderson Cancer Center, Gilbert, Arizona</aff><aff id="af3-fp-40-05s-064">
<label>c</label>Veterans Affairs Memphis Healthcare System, Tennessee</aff><aff id="af4-fp-40-05s-064">
<label>d</label>Emory University, Atlanta, 
<country>Georgia</country></aff><author-notes><corresp id="c1-fp-40-05S-064">Correspondence: Courtney Shires (<email>cshires1@gmail.com</email>)</corresp><fn id="fn1-fp-40-05s-064" fn-type="COI-statement"><p>
<bold>Author disclosures</bold>
</p><p>The authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article.</p></fn></author-notes><pub-date pub-type="ppub"><month>5</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>17</day><month>5</month><year>2023</year></pub-date><volume>40</volume><issue>Suppl 1</issue><issue-id pub-id-type="pmc-issue-id">445507</issue-id><fpage>S64</fpage><lpage>S67</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>19</day><month>09</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-09-20 11:25:21.367"><day>20</day><month>09</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Frontline Medical Communications Inc., Parsippany, NJ, USA.</copyright-statement><copyright-year>2023</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fp-40-05s-064.pdf"/><abstract><sec><title>Background</title><p>The correlation between head and neck squamous cell carcinoma (SCC) and human papillomavirus (HPV) has been of great interest. We aimed to study immunoexpression of the p16<sup>INK4a</sup> (p16) antigen, a surrogate marker for high-risk HPV infection, in oropharyngeal SCC among veterans to estimate HPV-related cancer and survival. Secondary aims included stratification of race and ethnicity, degree of tobacco and alcohol use, tumor location, stage, and age at diagnosis.</p></sec><sec><title>Methods</title><p>A retrospective electronic health record review was performed between January 1, 2000, and December 31, 2008, at a tertiary-level US Department of Veterans Affairs (VA) medical center for veterans who were treated for oropharyngeal SCC, had follow-up for a minimum of 2 years, and for whom paraffin-embedded tissue was available. Paraffin-embedded tissue was analyzed for p16 expression.</p></sec><sec><title>Results</title><p>We identified 66 veterans who met the inclusion criteria. p16 expression was observed in 29% of the patients. All patients were male with no difference in age at diagnosis between the groups. Among patients with p16-negative status, 60% were African American, whereas among patients with p16-postive status, 32% were African American (<italic toggle="yes">P</italic> = .04). Among patients with p16-postive status, 22% were tobacco-na&#239;ve, and 18% were alcohol-na&#239;ve vs 0% and 4%, respectively, of patients with p16-negative status (<italic toggle="yes">P</italic> = .005 and <italic toggle="yes">P</italic> = .12, respectively). Two-year survival was the same for both groups (<italic toggle="yes">P</italic> = .52).</p></sec><sec><title>Conclusions</title><p>We observed p16 expression in 29% of VA patients with oropharnygeal SCC, which was less than observed in non-VA populations. At presentation, both groups demonstrated a predilection for tonsil location and late stage without significant difference in age or disease-specific survival. Disparities in racial distribution and tobacco use between patients with and without p16-positive status appear like that reported in non-VA populations; however, the frequently reported younger age at presentation, lower stage, and improved prognosis were not observed.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>